Ma Huiyong, Murray James B, Luo Huadong, Cheng Xuemin, Chen Qiuxia, Song Chao, Duan Cong, Tan Ping, Zhang Lifang, Liu Jian, Morgan Barry A, Li Jin, Wan Jinqiao, Baker Lisa M, Finnie William, Guetzoyan Lucie, Harris Richard, Hendrickson Nicole, Matassova Natalia, Simmonite Heather, Smith Julia, Hubbard Roderick E, Liu Guansai
HitGen Inc. Building 6, No. 8 Huigu First East Road, Tianfu International Bio-Town, Shuangliu District Chengdu 610000 Sichuan P. R. China
Vernalis (R&D) Ltd Granta Park, Abington Cambridge CB21 6GB UK
RSC Med Chem. 2022 Aug 26;13(11):1341-1349. doi: 10.1039/d2md00197g. eCollection 2022 Nov 16.
We describe a novel approach for screening fragments against a protein that combines the sensitivity of DNA-encoded library technology with the ability of fragments to explore what will bind. Each of the members of the library consists of a fragment which is linked to a photoactivatable diazirine moiety. Split and pool synthesis combines each fragment with a set of linkers with the version of the library reported here containing some 70k different compounds, each with an individual DNA code. Incubation of the library with a protein sample is followed by photoactivation, washing and subsequent PCR and sequencing which allows the individual fragment hits to be identified. We illustrate how the approach allows successful hit fragment identification using only microgram quantities of material for two targets. PAK4 is a kinase for which conventional fragment screening has generated many advance leads. The as yet undrugged target, 2-epimerase, presents a more challenging active site for identification of hit compounds. In both cases, PAC-FragmentDEL identified fragments validated as hits by ligand-observed NMR measurements and crystal structure determination of off-DNA sample binding to the proteins.
我们描述了一种针对蛋白质筛选片段的新方法,该方法将DNA编码文库技术的灵敏度与片段探索结合能力相结合。文库的每个成员都由一个与可光活化的重氮嗪部分相连的片段组成。拆分和混合合成将每个片段与一组接头相结合,本文报道的文库版本包含约70k种不同化合物,每种化合物都有一个单独的DNA编码。将文库与蛋白质样品孵育,然后进行光活化、洗涤,随后进行PCR和测序,从而鉴定出单个片段命中物。我们说明了该方法如何仅使用微克量的材料针对两个靶标成功鉴定命中片段。PAK4是一种激酶,传统的片段筛选已为其产生了许多先导化合物。尚未有药物作用的靶标2-表异构酶,在鉴定命中化合物方面呈现出更具挑战性的活性位点。在这两种情况下,PAC-片段DEL鉴定出的片段通过配体观察NMR测量以及非DNA样品与蛋白质结合的晶体结构测定被确认为命中物。